Sterling Pharma Solutions Acquires CiVentiChem US Facility in Cary, North Carolina

GHO Capital Acquires Majority Stake in Sterling Pharma Solutions

February 28, 2019

Pharmaceuticals

GHO Capital has acquired a majority stake in Sterling Pharma Solutions alongside management. The investment will support Sterling's international expansion and accelerate growth of its specialist API development and GMP manufacturing capabilities from its UK base in Newcastle upon Tyne.

Sterling Pharma Solutions Acquires Alcami's Germantown (WI) API Facility

October 1, 2020

Pharmaceuticals

Sterling Pharma Solutions, a portfolio company of GHO Capital Partners, has acquired Alcami’s Germantown, Wisconsin API development and manufacturing facility. The facility expands Sterling’s US footprint and adds cGMP capacity for complex and hazardous API projects, including plant-scale hydrogenation and cryogenic reactions.

Sterling Pharma Solutions Acquires Novartis Ringaskiddy API Manufacturing Facility

January 11, 2023

Pharmaceuticals

Sterling Pharma Solutions, a GHO Capital portfolio company, has completed the acquisition of the Novartis API manufacturing facility in Ringaskiddy, County Cork, Ireland. The 111-acre site (with ~350 transferred employees and extensive commercial-scale API production capacity) expands Sterling's European manufacturing footprint and includes an ongoing supply agreement with Novartis.

Alcami Acquires TriPharm Services to Expand Sterile Fill‑Finish Capacity

January 17, 2020

Pharmaceuticals

Alcami Corporation has acquired TriPharm Services, a new sterile fill‑finish manufacturing center near Research Triangle Park, North Carolina. Funds affiliated with Alcami majority owner Madison Dearborn Partners made an additional equity investment to support Alcami's growth plan, while Ampersand Capital Partners rolled a portion of its TriPharm ownership into Alcami.

ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M

March 9, 2021

Pharmaceuticals

ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.

Cambrex Acquires Avista Pharma Solutions

January 2, 2019

Pharmaceuticals

Cambrex Corporation completed the acquisition of Avista Pharma Solutions from Ampersand Capital Partners in a transaction announced November 20, 2018 and completed January 2019 (reported consideration about $252 million). The deal brings Avista’s early‑stage drug development, analytical/testing and finished dosage capabilities (sites in Longmont, CO; Durham, NC; Agawam, MA; and Edinburgh, UK) into Cambrex’s global CDMO network to expand capabilities and cross‑sell services.